SCHEMBL3076765

SCHEMBL3076765

O=C(C1CCC(F)(F)CC1)N1CCCNCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.61
CHRNA3 P32297 1/20 0.61
CHRNA4 P43681 1/20 0.61
CHRNB3 Q05901 1/20 0.61
CHRNA6 Q15825 1/20 0.61
CHRM2 P08172 2/20 0.46
CHRM1 P11229 2/20 0.46
CHRM3 P20309 2/20 0.46
HPGD P15428 2/20 0.46
ALDH1A1 P00352 2/20 0.42
TSHR P16473 1/20 0.42
CNR2 P34972 1/20 0.41
CA2 P00918 1/20 0.41
CHKA P35790 1/20 0.41
ITGB3 P05106 3/20 0.40
ITGA2B P08514 3/20 0.40
GRM5 P41594 1/20 0.40
KMT2A Q03164 1/20 0.39
HTT P42858 1/20 0.38
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16207725 0.94 CHRNB2 (0.69) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL26126254 0.85 CHRNB2 (0.84) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL18390857 0.84 CHRNB2 (0.59) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL16238423 0.83 HPGD (0.67) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL1159331 0.83 CHRNB2 (0.74) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL1706129 0.83 CHRNB2 (0.74) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL16207607 0.80 CHRNB2 (0.58) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL2677418 0.78 ALDH1A1 (0.48) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL2676852 0.78 CHRNB2 (0.65) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL911817 0.77 CHRNB2 (0.83) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100261708-A1 Diazepane Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 US disclosed
US-20100261708-A1 Diazepane Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 US disclosed
US-20100261708-A1 Diazepane Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 US disclosed
WO-2009055357-A1 DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261708-A1 Diazepane Compounds Which Modulate The CB2 Receptor CNR1, CNR2, BDKRB2 CHRNB2 187/4885CHRNA3 87/4885CHRNA4 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.